SAREPTA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
SAREPTA THERAPEUTICS, INC. (SRPT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 6.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-02-28
- SAREPTA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 6.10%.
- SAREPTA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -2.00%.
- SAREPTA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -1.50%.
- SAREPTA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was -3.40%, a 197.14% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 6.10% 10-K · filed 2025-02-28 | |
| 2023-12-31 | -2.00% 10-K · filed 2025-02-28 | |
| 2022-12-31 | -1.50% 10-K · filed 2025-02-28 | -1.20% 10-K · filed 2023-02-28 |
| 2021-12-31 | -3.40% 10-K · filed 2024-02-28 | -3.00% 10-K · filed 2022-03-01 |
| 2020-12-31 | 3.50% 10-K · filed 2023-02-28 | |
| 2019-12-31 | -0.60% 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |